Cost-effectiveness of onabotulinumtoxinA for the treatment of wrist and hand disability due to upper-limb post-stroke spasticity in Scotland

European Journal of Neurology

Volumn 20, Issue 5, 2013, Pages 773-780

  Doan, Q V ^a   Gillard, P ^b   Brashear, A ^c   Halperin, M ^a   Hayward, E ^d   Varon, S ^b   Lu, Z J ^a  

^a Outcomes Insights Inc   (United States)

^b ALLERGAN INC   (United States)

^c WAKE FOREST BAPTIST HEALTH   (United States)

^d ALLERGAN PLC   (United States)

Author keywords

Botulinum toxin; Cost effectiveness; OnabotulinumtoxinA; Spasticity; Stroke

Indexed keywords

BOTULINUM TOXIN A;

ADULT; ARM; ARTICLE; CAREGIVER BURDEN; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; FEMALE; HEALTH CARE UTILIZATION; HUMAN; INTERMETHOD COMPARISON; MACHINE LEARNING; MAJOR CLINICAL STUDY; MALE; MODEL; MORTALITY; NATIONAL HEALTH SERVICE; PATIENT CARE; PRIORITY JOURNAL; PROFESSIONAL PRACTICE; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); SPASTICITY; UNITED KINGDOM; UPPER LIMB POST STROKE SPASTICITY;

AGED; BOTULINUM TOXINS, TYPE A; CLINICAL TRIALS AS TOPIC; COST OF ILLNESS; COST-BENEFIT ANALYSIS; FEMALE; HAND; HEALTH CARE COSTS; HEALTH SERVICES; HUMANS; MALE; MODELS, ECONOMIC; MUSCLE SPASTICITY; NEUROTOXINS; QUALITY-ADJUSTED LIFE YEARS; SCOTLAND; STROKE; UPPER EXTREMITY; WRIST;

EID: 84876310594     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.12062     Document Type: Article

References (26)

1. Scottish Intercollegiate Guidelines Network. Management of Patients with Stroke: Rehabilitation, Prevention and Management of Complications, and Discharge Planning. A National Clinical Guideline. http://www.sign.ac.uk/pdf/sign118.pdf. (accessed 01/08/2010).
2. Sommerfeld DK, Eek EU, Svensson AK, Holmqvist LW, von Arbin MH. Spasticity after stroke: its occurrence and association with motor impairments and activity limitations. Stroke 2004; 35: 134-139.
3. Urban PP, Wolf T, Uebele M, et al. Occurence and clinical predictors of spasticity after ischemic stroke. Stroke 2010; 41: 2016-2020.
4. Welmer AK, von AM, Widen HL, Sommerfeld DK. Spasticity and its association with functioning and health-related quality of life 18 months after stroke. Cerebrovasc Dis 2006; 21: 247-253.
5. Lundstrom E, Terent A, Borg J. Prevalence of disabling spasticity 1 year after first-ever stroke. Eur J Neurol 2008; 15: 533-539.
6. Watkins CL, Leathley MJ, Gregson JM, Moore AP, Smith TL, Sharma AK. Prevalence of spasticity post stroke. Clin Rehabil 2002; 16: 515-522.
7. Gormley ME Jr, O'Brien CF, Yablon SA. A clinical overview of treatment decisions in the management of spasticity. Muscle Nerve Suppl 1997; 6: S14-S20.
8. Brashear A, Zafonte R, Corcoran M, et al. Inter- and intrarater reliability of the Ashworth Scale and the Disability Assessment Scale in patients with upper-limb poststroke spasticity. Arch Phys Med Rehabil 2002; 83: 1349-1354.
9. Elovic EP, Brashear A, Kaelin D, et al. Repeated treatments with botulinum toxin type a produce sustained decreases in the limitations associated with focal upper-limb poststroke spasticity for caregivers and patients. Arch Phys Med Rehabil 2008; 89: 799-806.
10. Royal College of Physicians, British Society of Rehabilitation Medicine, Chartered Society of Physiotherapy, Association of Chartered Physiotherapists Interested in Neurology. Spasticity in adults: management using botulinum toxin. National guidelines. http://www.rcplondon.ac.uk/pubs/contents/6988a14a-1179-4071-8f56-dc2a865f0a43.pdf. (accessed 05/08/2010).
11. Intercollegiate Stroke Working Party. National clinical guideline for stroke, 3rd edn. London: Royal College of Physicians, 2008.
12. Wallesch CW, Maes ELP, Bartels C. Cost-effectiveness of botulinum toxin type A injection in patients with spasticity following stroke: a German perspective. Eur J Neurol 1997; 4(suppl 2): S53-S57.
13. Radensky PW, Archer JW, Dournaux SF, O'Brien CF. The estimated cost of managing focal spasticity: a physician practice patterns survey. Neurorehabil Neural Repair 2001; 15: 57-68.
14. Ward A, Roberts G, Warner J, Gillard S. Cost-effectiveness of botulinum toxin type a in the treatment of post-stroke spasticity. J Rehabil Med 2005; 37: 252-257.
15. Brashear A, Gordon MF, Elovic E, et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med 2002; 6: 395-400.
16. Lewsey JD, Jhund PS, Gillies M, et al. Age- and sex-specific trends in fatal incidence and hospitalized incidence of stroke in Scotland, 1986 to 2005. Circ Cardiovasc Qual Outcomes 2009; 2: 475-483.
17. Gordon MF, Brashear A, Elovic E, et al. Repeated dosing of botulinum toxin type A for upper limb spasticity following stroke. Neurology 2004; 10: 1971-1973.
18. EuroQol Group. EQ-5D User Guide: Basic Information on How to Use EQ-5D. Available from: URL: http://www.euroqol.org/fileadmin/user_upload/Documenten/PDF/User_Guide_v2_March_2009.pdf (accessed 01/08/2010)
19. Brazier J, Deverill M, Green C, Harper R, Booth A. A review of the use of health status measures in economic evaluation. Health Technol Assess 1999; 3: 1-164.
20. Doan QV, Brashear A, Gillard PJ, et al. Relationship between disability and health-related quality of life and caregiver burden in patients with upper limb poststroke spasticity. PM R 2012; 4: 4-10.
21. General Register Office for Scotland. Sottish Decennial Life Tables 2000-2002. http://www.gro-scotland.gov.uk/statistics/publications-and-data/life-expectancy/life-expectancy-at-scotland-level/index.html. (accessed 05/08/2010).
22. Carter AM, Catto AJ, Mansfield MW, Bamford JM, Grant PJ. Predictive variables for mortality after acute ischemic stroke. Stroke 2007; 38: 1873-1880.
23. Shaw L, Rodgers H, Price C, et al. BoTULS: a multicentre randomised controlled trial to evaluate the clinical effectiveness and cost-effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type A. Health Technol Assess 2010; 14: 49-60.
24. UK 2009 Annual Survey of Hours and Earnings.
25. Phillips B, Sackett D, Badenoch D, Straus S, Haynes B, Dawes M. Oxford Centre for Evidence-based Medicine - Levels of Evidence. http://www.cebm.net/index.aspx?o=1025. (accessed 12/01/2012).
26. Lewsey JD, Gillies M, Jhund PS, et al. Sex differences in incidence, mortality, and survival in individuals with stroke in Scotland, 1986 to 2005. Stroke 2009; 40: 1038-1043.